Autolus Therapeutics

Autolus Therapeutics

Autolus is a biopharmaceutical company focused on programmed T-cell therapies for treatment of cancer. Autolus was founded in 2014 and is based in London, UK. Autolus Limited is a subsidiary of Autolus Holdings (UK) Limited.

Autolus develops and commercializes engineered T-cell immunotherapy products to treat cancer. Autolus supplies engineering chimeric antigen receptors (CAR) T-cell products that kill malignant cells and protect from malignancy in the long-term. The company provides T-cell products for hematological and solid tumors.

T-cells normally detect and eliminate abnormal or cancerous cells in the body but sometimes cells escape detection and develop into tumors. Autolus programs T-cells to recognize and destroy tumour cells by transferring a gene into T-cells so they express Chimeric Antigen Receptors (CARs) or T-cell receptors (TCRs) that recognize targets on the surface of malignant cells. For their process Autolus uses their own proprietary viral vector and semi-automated cell manufacturing processes. The company has a collaboration partnership with AbCellera Biologics Inc. for a project in antibody discovery.

Pipeline and products

Autolus is developing AUTO1, a programmed T cell therapy targeting CD19 to treat acute lymphoblastic B cell leukemia (ALL). The therapy designed to reduce the risk of severe cytokine release syndrome, is in a Phase I clinical trial as of 2019. Cytokine release syndrome is a condition that can occur after immunotherapy threatment and that can be life threatening. The therapy can cause immune cells to release a large release of cytokines into the blood and lead to symptoms like fever, nausea, headache, rask, rapid hearbeat, low blood pressure and trouble breathing. AUTO1 uses a novel CD19 binder that allows rapid disengagement of CAR T cells after target cell encounter and kill.

Pre-clinical and clinical data from an ongoing Phase I CARPALL trial of AUTO1 were published in Nature Medicine in 2019. In the Phase I clinical trial 86% of the pediatric ALL patients (n=14) showed molecular complete remission after a single dose with a median duration of remission of 7.4 months and no severe cytokine release syndrome.

AUTO2 is a programmed T cell therapy with two targets, for the treatment of relapsed or refractory multiple myeloma. AUTO2 is in PhaseI/II clinical trials as of 2019.

AUTO3 is a dual-targeting programmed T cell therapy for treating relapsed or refractory diffuse large B-cell lymphoma, which is in Phase I/II clinical trials as of 2019.

AUTO4 is a programmed T cell therapy for treatment of peripheral T-cell lymphoma and is in Phase I/II clinical trials as of 2019.

AUTO6 is a programmed T cell therapy for treatment of neuroblastoma.


September 2, 2019
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

Nature Medicine (2019)

Authors from Autolus and various cancer research institutes in London, UK presented pre-clinical and clinical data on the programmed T cell therapy called AUTO1.

September 2017
Autolus Therapeutics raises a $80,000,000 series C round from Arix Bioscience plc, Cormorant Asset Management, Nextech Invest, Syncona Investment Management and Woodford Investment Management.
Autolus Therapeutics was founded by Martin Pule.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Autolus funding round, September 2017
September 2017
1 Result
Results per page:
Page 1 of 1



Dr. Christian Martin Itin

Chairman, CEO

Dr. Jim Faulkner, PhD

Head of Manufacturing

Dr. Louise Holliday

Head of Intellectual Property

Dr. Martin Pulé

Founder, CSO

Mr. Christopher Vann


Further reading


Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)

Autolus Therapeutics plc


Biotech to create 170 jobs, invest $28M in new Rockville HQ

Katie Arcieri


New CAR T-cell therapy for leukemia associated with fewer harmful side effects

Henry Killworth


September 4, 2019

Documentaries, videos and podcasts


Cell Therapy Commercialization in Oncology

January 8, 2019




Nick Paul
January 6, 2021
Autolus Therapeutics is set to reduce its headcount by around 20% and seek a partner for one of its dual-targeted CAR-T candidates. The changes will increase Autolus' focus on CD19 CAR-T cell therapy AUTO1 ahead of the anticipated delivery of pivotal data on the candidate next year.


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.